Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.32 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.32 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.30 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23319964 | 1.00 | ATM (0.45) | ATMEPHX2PARP1ALOX15KCNA3 | |
| Formic Acid SCHEMBL28881328 | 0.92 | ATM (0.40) | ATMEPHX2PARP1KCNA3METAP2 | |
| SCHEMBL425737 | 0.87 | — | — | |
| SCHEMBL28439266 | 0.85 | — | — | |
| Water SCHEMBL8681204 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL11162708 | 0.85 | — | — | |
| SCHEMBL18084116 | 0.81 | ATM (0.45) | ATMALOX15KCNA3SERPINE1EPHX1 | |
| SCHEMBL14609330 | 0.81 | ATM (0.45) | ATMALOX15KCNA3SERPINE1EPHX1 | |
| SCHEMBL28669754 | 0.81 | ATM (0.45) | ATMDPP4DPP7 | |
| Methyl Carbamate SCHEMBL30557725 | 0.80 | ATM (0.41) | ATMALOX15KCNA3EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190855-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2024-06-13 | — | — | US | disclosed |
| CN-109641906-B | Heteroaryl substituted aminopyridine compounds | 百时美施贵宝公司 | 2021-10-01 | — | — | CN | disclosed |
| US-10618903-B2 | Heteroaryl substituted aminopyridine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-04-14 | — | — | US | disclosed |
| EP-3475270-B1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20190292191-A1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292191-A1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | IRAK4, IRAK3, IRAK2 | ATM 826/4885EPHX2 2336/4885PARP1 425/4885 |
| US-10618903-B2 | Heteroaryl substituted aminopyridine compounds | IRAK4, IRAK3, IRAK2 | ATM 826/4885EPHX2 2336/4885PARP1 425/4885 |
| US-20240190855-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | CDK3, CDK8, CDK6 | ATM 326/4885EPHX2 2679/4885PARP1 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.